GLYCEMIC CONTROL AND PREVALENCE OF GASTROPATHIES AND GASTROPARESIS IN PATIENTS OF TYPE 2 DIABETES MELLITUS: A CROSS-SECTIONAL STUDY
DOI:
https://doi.org/10.71000/bnkh7975Keywords:
Diabetes Mellitus Type 2, Endoscopy, Gastropathies, Gastroparesis, Gastric Emptying, Glycated Hemoglobin, Upper Gastrointestinal DisordersAbstract
Background: Diabetes mellitus is frequently associated with gastrointestinal motility disorders, with gastropathies and gastroparesis representing significant yet often underdiagnosed complications. These conditions contribute to impaired glycaemic control, reduced quality of life, and increased healthcare utilization. Early detection is essential, particularly in regions where local data are limited and structured screening practices are not routinely implemented. Understanding the magnitude of these complications among individuals with type 2 diabetes is therefore crucial for improving targeted clinical management and guiding preventative strategies within local healthcare settings.
Objective: To determine the frequency of gastropathies and gastroparesis in individuals with type 2 diabetes mellitus.
Methods: This cross-sectional study was conducted at the Department of Medicine, Doctors Hospital & Medical Center, Lahore, from August 2024 to February 2025. A total of 150 individuals with type 2 diabetes who met the inclusion criteria were enrolled through consecutive sampling from the outpatient department. All participants underwent upper gastrointestinal endoscopy to assess the presence of gastropathies and gastroparesis. Demographic and clinical data—including age, gender, HbA1c, and duration of diabetes—were recorded using a structured proforma. Data entry and statistical analysis were performed using SPSS version 25, with descriptive statistics used to summarize key findings.
Results: The study cohort had a mean age of 50.31 ± 11.66 years, with 80 individuals (53.3%) aged below 50 years. Males accounted for 62.7% of the sample. The mean HbA1c was 10.60 ± 2.17%, and 106 participants (70.7%) had uncontrolled glycaemic levels. The mean duration of diabetes was 8.39 ± 5.28 years. Gastropathies were detected in 68 individuals (45.3%), whereas gastroparesis was observed in 76 individuals (50.7%).
Conclusion: Gastropathies and gastroparesis were frequently identified among individuals with type 2 diabetes, underscoring the importance of incorporating routine gastrointestinal screening into diabetic care to ensure timely detection and management.
References
Dinavari MF, Sanaie S, Rasouli K, Faramarzi E, Molani-Gol R. Glycemic control and associated factors among type 2 diabetes mellitus patients: a cross-sectional study of Azar cohort population. BMC Endocrine Disorders 2023;23(1):273.
Ong KL, Stafford LK, McLaughlin SA, Boyko EJ, Vollset SE, Smith AE, et al. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. The Lancet 2023;402(10397):203-34.
Sachdeva A, Ahmed N. Gastrointestinal Motility Disorders: Understanding Pathophysiology and Treatment Options. Medical Letter 2025;2:60-5.
Jalleh RJ, Jones KL, Rayner CK, Marathe CS, Wu T, Horowitz M. Normal and disordered gastric emptying in diabetes: recent insights into (patho) physiology, management and impact on glycaemic control. Diabetologia 2022;65(12):1981-93.
Huang W, Xie C, Albrechtsen NJW, Jones KL, Horowitz M, Rayner CK, et al. The ‘early’postprandial glucagon response is related to the rate of gastric emptying in type 2 diabetes. Peptides 2023;161:170941.
Jalleh RJ, Jones KL, Rayner CK, Marathe CS, Wu T, Horowitz M. Normal and disordered gastric emptying in diabetes: recent insights into (patho)physiology, management and impact on glycaemic control. Diabetologia 2022;65(12):1981-93.
Petri M, Singh I, Baker C, Underkofler C, Rasouli N. Diabetic gastroparesis: An overview of pathogenesis, clinical presentation and novel therapies, with a focus on ghrelin receptor agonists. Journal of Diabetes and its Complications 2021;35(2):107733.
Lacy BE, Wise JL, Cangemi DJ. Gastroparesis: time for a paradigm change. Current Opinion in Gastroenterology 2023;39(6):503-11.
Degisors S, Caiazzo R, Dokmak S, Truant S, Aussilhou B, Eveno C, et al. Delayed gastric emptying following distal pancreatectomy: incidence and predisposing factors. HPB 2022;24(5):772-81.
Mekaroonkamol P, Tiankanon K, Rerknimitr R. A new paradigm shift in gastroparesis management. Gut and Liver 2022;16(6):825.
Yang DY, Camilleri M. The goals for successful development of treatment in gastroparesis. Neurogastroenterology & Motility 2024;36(10):e14849.
Wifi M-N, El-Sherbiny M, Mohamed RS, Kandeel A, Rizk SE. Clinical insights into diabetic gastroparesis: gastric scintigraphy-based diagnosis and treatment outcomes. BMC Gastroenterology 2025;25(1):640.
Li L, Wang L, Long R, Song L, Yue R. Prevalence of gastroparesis in diabetic patients: a systematic review and meta-analysis. Scientific Reports 2023;13(1):14015.
Xu S, Liang S, Pei Y, Wang R, Zhang Y, Xu Y, et al. TRPV1 Dysfunction Impairs Gastric Nitrergic Neuromuscular Relaxation in High-Fat Diet-Induced Diabetic Gastroparesis Mice. Am J Pathol. 2023;193(5):548-57.
Lewis DM. A Systematic Review of Exocrine Pancreatic Insufficiency Prevalence and Treatment in Type 1 and Type 2 Diabetes. Diabetes Technol Ther. 2023;25(9):659-72.
Andrews CN, Woo M, Buresi M, Curley M, Gupta M, Tack J, et al. Prucalopride in diabetic and connective tissue disease-related gastroparesis: Randomized placebo-controlled crossover pilot trial. Neurogastroenterol Motil. 2021;33(1):e13958.
Li L, Wang L, Long R, Song L, Yue R. Prevalence of gastroparesis in diabetic patients: a systematic review and meta-analysis. Sci Rep. 2023;13(1):14015.
van Zuylen ML, Siegelaar SE, Plummer MP, Deane AM, Hermanides J, Hulst AH. Perioperative management of long-acting glucagon-like peptide-1 (GLP-1) receptor agonists: concerns for delayed gastric emptying and pulmonary aspiration. Br J Anaesth. 2024;132(4):644-8.
Jalleh RJ, Jones KL, Rayner CK, Marathe CS, Wu T, Horowitz M. Normal and disordered gastric emptying in diabetes: recent insights into (patho)physiology, management and impact on glycaemic control. Diabetologia. 2022;65(12):1981-93.
Ghazanfar H, Javed N, Qasim A, Sosa F, Altaf F, Khan S, et al. Is it necessary to stop glucagon-like peptide-1 receptor agonists prior to endoscopic procedure? A retrospective study. World J Gastroenterol. 2024;30(26):3221-8.
Nadeem D, Taye M, Still MD, McShea S, Satterfield D, Dove JT, et al. Effects of glucagon-like peptide-1 receptor agonists on upper endoscopy in diabetic and nondiabetic patients. Gastrointest Endosc. 2024;100(4):745-9.
Tseng PH, Chao CC, Cheng YY, Chen CC, Yang PH, Yang WK, et al. Diabetic visceral neuropathy of gastroparesis: Gastric mucosal innervation and clinical significance. Eur J Neurol. 2022;29(7):2097-108.
Jalleh RJ, Plummer MP, Marathe CS, Umapathysivam MM, Quast DR, Rayner CK, et al. Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide. J Clin Endocrinol Metab. 2024;110(1):1-15.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Muhammad Usman Ahmed Kamal, Muzammal Aslam Kataria, Eisha Ashiq, Ali Anwar, Zamman Saqib, Ubaid Anjum (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
